Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $2.21 · Revenue $14.59B · 3 analysts
Est. EPS $2.14 · Revenue $14.76B · 3 analysts
Est. EPS $8.77 · Revenue $57.15B · 7 analysts
Est. EPS $2.33 · Revenue $14.32B · 1 analysts
EPS $1.71 · Revenue $14.42B
EPS $1.65 · Revenue $13.52B
$4.67 per share
$4.67 per share
EPS $7.19 · Revenue $54.81B
EPS $2.02 · Revenue $14.36B
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $54.8B | +6.0% | +6.6% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $14.1B | +17.7% | +3.5% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +75.0% | -0.2% | +0.1% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | +31.2% | +10.8% | +4.9% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | +25.6% | +11.1% | -2.9% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $17.7B | +28.1% | +94.0% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +32.3% | +20.9% | +82.0% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 80.3% | +13.1% | -3.3% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 1.12x | +7.9% | +1.6% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $115.6B | +13.0% | +3.0% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | 7.19 vs 8.93 | -19.5% | 1.71 vs 2.17 | -21.3% |
| Revenue Surprise | $54.8B vs $55.5B | -1.2% | $14.4B vs $14.1B | +2.5% |
Operator Good afternoon, and welcome to the Novartis Q2 2026 results release conference call and live webcast. Please note that during the presentation, all participants will be in a listen-only mode and the conference is being recorded. After the presentation, there will be an opportunity to ask questions by pressing star one and one at any time during the conference. Please limit yourself to one question and return to the queue for any follow-ups. A recording of the conference call, including the Q&A session, will be available on our website shortly after the call ends. With that, I would like to hand over to Mr. Nigel Trotman, Head of Business Planning, Analysis and Digital Finance. Please go ahead, sir. Nigel Trotman Thank you, Sharon. Good morning and good afternoon, welcome everyone to our Q2 2026 conference call. The information presented today contains forward-looking statements that involve known and unknown risks, uncertainties, and other factors. These may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. For a description of some of these factors, please refer to the company's Form 20-F and its most recent quarterly results on Form 6-K that respectively were filed with and furnished to the U.S. Securities and Exchange Commission. Before we get started, as a reminder, please kindly limit yourselves to one question at a time and we will cycle through the queue as needed. With that, I will hand over to Vas. Vas Narasimhan Thank you, Nigel. Thanks everyone for joining today's conference call. Moving to slide four. As you saw in the results we released earlier today, Novartis delivered strong performance across our priority brands and launches while advancing the pipeline, allowing us to return to growth in the second quarter. The business grew 1% in constant currencies in USD, we had flat core operating income at $5.9 billion. Mukul will go through the numbers in more detail later on in the call, we are reaffirming our full year guidance for 2026. We also had some important pipeline highlights, which I will talk about more during the course of the conference call, including updated KISQALI OS data, the del-brax biomarker data in FSHD, as well as some other regulatory milestones we were able to deliver over the course of the quarter. Moving to slide five. Our growth drivers continued a strong trajectory in quarter two. They were up 36% in constant currencies. Some of the highlights include strong performance from KISQALI, Cosentyx, Scemblix, solid performance from PLUVICTO, and strong performance as well from LEQVIO. Overall taken together, these growth drivers are performing strongly. We believe that gives us momentum going into the second half of the year as we now move beyond the Entresto patent expiry and set us up well to deliver on our midterm growth guidance. Moving to slide six. KISQALI was up 43% in constant currencies on the quarter. …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Vasant Narasimhan | Chief Executive Officer | USD 9,408,090 | — | 1976 | Active |
Victor Bulto | President of US | USD 4,153,335 | Male | 1978 | Active |
Mukul Mehta | Chief Financial Officer | USD 3,772,334 | Male | 1973 | Active |
Patrick Horber | President of International | USD 3,398,524 | — | 1970 | Active |
Karen L. Hale | Chief Legal & Compliance Officer | USD 2,661,447 | Female | 1968 | Active |
Steffen Lang | President of Operations | USD 2,654,010 | Male | 1967 | Active |
Robert Kowalski | Chief People & Organization Officer | USD 2,386,336 | — | 1968 | Active |
Evan Beckman | Global Head of Translational Medicine at Novartis Institute for BioMedical Research | — | Male | — | Active |
Paul Penepent | Head of Group Financial Reporting and Accounting | — | — | — | Active |
Sloan Simpson | Global Head of Investor Relations | — | Female | — | Active |
Axiom Investment Management LLC purchased a new stake in shares of Novartis AG (NYSE: NVS) in the first quarter, according to its most recent filing with the SEC. The firm purchased 3,326 shares of the company's stock, valued at approximately $508,000. Several other hedge funds have also recently bought and sold shares of
Ashton Thomas Securities LLC purchased a new stake in Novartis AG (NYSE: NVS) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 22,962 shares of the company's stock, valued at approximately $3,507,000. A number of other institutional investors have also recently
These companies' recent headwinds shouldn't lead to decreased payouts.
Entropy Technologies LP acquired a new position in shares of Novartis AG (NYSE: NVS) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 12,359 shares of the company's stock, valued at approximately $1,888,000. A number of other large
Cetera Investment Advisers grew its position in shares of Novartis AG (NYSE: NVS) by 13.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 203,045 shares of the company's stock after acquiring an additional 24,096 shares during the quarter.
